Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kazia Therapeutics Limited
KZIA | US
12.26
USD0.44
3.72%
KZIA | US
Loading StockChartView...
About Kazia Therapeutics Limited
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/12/2023
As of date
24/04/2026
Close
12.26
Open
12.11
High
12.40
Low
11.76
Kazia Therapeutics Limited an oncology-focused biotechnology company develops anti-cancer drugs. Its lead development candidate is Paxalisib a small molecule brain-penetrant inhibitor of the PI3K/Akt/mTor pathway which is developed as a potential therapy for glioblastoma. It is also developing EVT801 an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney Australia.
View LessKZIA | US
Risk
121.8
Sharpe
1.67
Luna's Score
64/100
Recommendation
Hold
Luna says (KZIA | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
84.7%1 month
121.8%3 months
114.8%6 months
160.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.76
Debt to equity
0.07
Debt to assets
0.01
Ent. to EBITDA
-0.71
Ent. to rev.
0.94
PEG
-
Other Fundamentals
EBITDA
-17.52M
MarketCap
408.08M
MarketCap(USD)
408.08M
Div. yield
-
Op. margin
-100.00M
Erngs. growth
-
Rev. growth
35.60
Ret. on equity
-186.37
Short ratio
0.20
Short perc.
1.00
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.99
Range1M
5.50
Range3M
7.54
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.84
Price X volume
2.76M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.71 | 0.53 | Cheaper |
| Ent. to Revenue | 0.94 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.76 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 114.81 | 72.80 | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 408.08M | 3.66B | Emerging |
